Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170071 | 0.79 | ALDH1A1 (0.61) | TSHRCYP3A4TP53ALDH1A1GLA | |
| SCHEMBL17732006 | 0.78 | TSHR (1.00) | TSHRCYP3A4TP53ALDH1A1GLA | |
| SCHEMBL2183787 | 0.76 | TP53 (1.00) | TSHRCYP3A4TP53ALDH1A1GLA | |
| SCHEMBL9001683 | 0.73 | ALDH1A1 (0.64) | TSHRCYP3A4TP53ALDH1A1GLA | |
| SCHEMBL6102166 | 0.72 | TP53 (0.80) | TSHRCYP3A4TP53ALDH1A1GLA | |
| SCHEMBL3486247 | 0.72 | TP53 (0.71) | TSHRCYP3A4TP53ALDH1A1GLA | |
| SCHEMBL3145081 | 0.71 | TSHR (0.58) | TSHRCYP3A4TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL3454767 | 0.71 | MEN1 (0.70) | TSHRCYP3A4TP53ALDH1A1KMT2A | |
| SCHEMBL4065279 | 0.71 | TP53 (0.69) | TSHRTP53ALDH1A1GLASMN1; SMN2 | |
| SCHEMBL18275347 | 0.70 | KMT2A (0.56) | TSHRCYP3A4TP53ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958347-B2 | Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists | PFIZER INC. (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1578728-A1 | 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004054981-A1 | 5-AMINOPHENANTHRIDINE DERIVATIVES AS NPY-5 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040122038-A1 | NPY-5 antagonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122038-A1 | NPY-5 antagonists | NPY5R, NPY1R, NPY2R | TSHR 155/4885CYP3A4 3008/4885TP53 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.